Extended Data Fig. 8: ORM2 recombinant protein treatment improves liver steatosis in db/db mice.
From: Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis
Related to Fig. 8. a-j, db/db male mice were intraperitoneally injected with recombinant ORM2 protein (0.1 mg/kg, 1.0 mg/kg) or vehicle control (PBS, 0) for 10 days. a-f, Body weight (a), average daily food intake for 3 consecutive days (b), liver/body weight ratio (c), hepatic TG levels (d), plasma TG (e) and TC levels (f) from three groups of db/db mice. (a-f) n = 8 biologically independent mice per condition. g, Macroscopic appearance of liver, H&E and Oil Red O staining of liver sections. Scale bar, 50 μm. Representative result from three biologically independent mice. h, Relative mRNA levels of genes related to de novo lipogenesis in the livers. n = 8 biologically independent mice per condition. i, Protein levels of lipogenic genes in the livers. n = 4 biologically independent mice per condition. j. Immunoblots of AMPK and mTOR signaling pathways in the livers. n = 4 biologically independent mice per condition. Data are shown as mean ± SEM (a-f, h). P values are determined by one-way ANOVA followed by Dunnett’s multiple comparisons test (a-f, h).
